Disease Landscape and Forecast Insights

MARKET OUTLOOK SLE is an autoimmune disease characterized by varied symptoms ranging from general fatigue to serious organ manifestations. Options available to treat SLE are limited, with…

Stage of disease, resectability of the primary tumor, and BRAF-mutation status (in the unresectable or metastatic setting) are key parameters that influence the treatment paradigm of malignant…

There have been significant economic benefits in Europe since the approval of the first biosimilar more than a decade ago. Although the first FDA biosimilar approval was in 2015, biosimilars are…

Dyslipidemia refers to abnormalities in lipids and lipoproteins in the circulation and is a key modifiable risk factor for cardiovascular (CV) disease. The most common lipid abnormalities include…

The treatment landscape for colorectal cancer is based on chemotherapies and targeted agents, although the latter (e.g., Avastin, Erbitux, Vectibix) are currently confined to the metastatic setting…

Five TNF inhibitors, five biologics with alternative mechanisms of action, and two JAK inhibitors are approved for the treatment of rheumatoid arthritis (RA) in the EU5 (France, Germany, Italy,…

Market Outlook The asthma market in the EU5 is highly competitive. A large number of approved agents are available including maintenance therapies—LABA/ICSFDC (e.g., GSK’s Seretide and…

MARKET OUTLOOK Psoriasis Current Treatment: Physician Insights probes the current and future use of topical agents, phototherapy, and systemic therapies in the treatment of mild, moderate, and…

Introduction: Non-Hodgkin’s lymphoma (NHL) is a heterogeneous group of malignancies that can be broadly classified into indolent and aggressive subtypes. The treatment algorithm for NHL …

According to DRG epidemiology, more than 33 million people in the EU5 suffer from migraines and over 10% of migraineurs suffer from chronic migraine (CM). Migraine prophylaxis is a core treatment…

Osteoarthritic (OA) pain is a prevalent subtype of chronic pain, affecting more than 43 million individuals in the EU5. OA pain treatment decisions are driven primarily by rheumatologists,…

Prior to the launch of Hemlibra, the hemophilia market consisted solely of factor-based products. The use of factor concentrate is highly varied; brand-dependent dosing and infusion frequencies,…